PUMA BIOTECHNOLOGY, INC. Operating Lease, Expense
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Operating Lease, Expense of $300.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-06
- PUMA BIOTECHNOLOGY, INC. operating lease, expense for the quarter ending 2026-06-30 was $300.00K, a 70.00% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. operating lease, expense for the quarter ending 2026-03-31 was $1.10M, a 8.33% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. operating lease, expense for the quarter ending 2025-12-31 was $1.10M, a 8.33% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. operating lease, expense for the quarter ending 2025-09-30 was $1.10M, a 8.33% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. operating lease, expense for fiscal 2025 was $4.50M, a 8.16% decline from fiscal 2024.
- PUMA BIOTECHNOLOGY, INC. operating lease, expense for fiscal 2024 was $4.90M, a 0.00% change from fiscal 2023.
- PUMA BIOTECHNOLOGY, INC. operating lease, expense for fiscal 2023 was $4.90M, a 0.00% change from fiscal 2022.
- PUMA BIOTECHNOLOGY, INC. operating lease, expense for fiscal 2022 was $4.90M, a 3.92% decline from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $300.00K 10-Q · filed 2026-08-06 | $1.40M 10-Q · filed 2026-08-06 | $2.50M derived: sum of 3 quarters · filed 2026-08-06 | $3.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.10M 10-Q · filed 2026-05-07 | $2.20M derived: sum of 2 quarters · filed 2026-05-07 | $3.30M derived: sum of 3 quarters · filed 2026-05-07 | $4.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.20M derived: sum of 2 quarters · filed 2026-02-26 | $3.20M derived: sum of 3 quarters · filed 2026-08-06 | $4.50M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.10M 10-Q · filed 2025-11-06 | $2.10M derived: sum of 2 quarters · filed 2026-08-06 | $3.40M 10-Q · filed 2025-11-06 | $4.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.00M 10-Q · filed 2026-08-06 | $2.20M 10-Q · filed 2026-08-06 | $3.40M derived: sum of 3 quarters · filed 2026-08-06 | $4.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.20M 10-Q · filed 2026-05-07 | $2.40M derived: sum of 2 quarters · filed 2026-05-07 | $3.60M derived: sum of 3 quarters · filed 2026-05-07 | $4.80M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.40M derived: sum of 2 quarters · filed 2026-02-26 | $3.60M derived: sum of 3 quarters · filed 2026-02-26 | $4.90M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.20M 10-Q · filed 2025-11-06 | $2.40M derived: sum of 2 quarters · filed 2025-11-06 | $3.70M 10-Q · filed 2025-11-06 | $4.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.20M 10-Q · filed 2025-08-07 | $2.40M 10-Q · filed 2025-08-07 | $3.60M derived: sum of 3 quarters · filed 2026-02-26 | $4.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.20M 10-Q · filed 2025-05-08 | $2.40M derived: sum of 2 quarters · filed 2026-02-26 | $3.60M derived: sum of 3 quarters · filed 2026-02-26 | $4.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.40M derived: sum of 2 quarters · filed 2026-02-26 | $3.60M derived: sum of 3 quarters · filed 2026-02-26 | $4.90M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.20M 10-Q · filed 2024-11-07 | $2.40M derived: sum of 2 quarters · filed 2024-11-07 | $3.70M 10-Q · filed 2024-11-07 | $4.80M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.20M 10-Q · filed 2024-08-01 | $2.40M 10-Q · filed 2024-08-01 | $3.60M derived: sum of 3 quarters · filed 2025-02-27 | $4.80M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.20M 10-Q · filed 2024-05-02 | $2.40M derived: sum of 2 quarters · filed 2025-02-27 | $3.60M derived: sum of 3 quarters · filed 2025-02-27 | $4.80M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.40M derived: sum of 2 quarters · filed 2025-02-27 | $3.60M derived: sum of 3 quarters · filed 2025-02-27 | $4.90M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.20M 10-Q · filed 2023-11-02 | $2.40M derived: sum of 2 quarters · filed 2023-11-02 | $3.70M 10-Q · filed 2023-11-02 | $5.00M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $1.20M 10-Q · filed 2023-08-03 | $2.50M 10-Q · filed 2023-08-03 | $3.80M derived: sum of 3 quarters · filed 2024-02-29 | $5.10M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $1.30M 10-Q · filed 2023-05-04 | $2.60M derived: sum of 2 quarters · filed 2024-02-29 | $3.90M derived: sum of 3 quarters · filed 2024-02-29 | $5.20M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $2.60M derived: sum of 2 quarters · filed 2024-02-29 | $3.90M derived: sum of 3 quarters · filed 2024-02-29 | $5.10M 10-K · filed 2024-02-29 |
| 2021-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $2.60M derived: sum of 2 quarters · filed 2022-11-03 | $3.80M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $2.50M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $1.20M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $5.10M 10-K · filed 2023-03-02 | |||
| 2019-12-31 | $5.10M 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |